Min Lu

Min Lu

Auto-generated profile, based on publicly available information

Min Lu

Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2022 in Science Translational Medicine
Verified
Journal Article
Open access
MAMoiez Ali
Moiez Ali
MLMin Lu
Min Lu
HAHazel Xiaohui Ang
Hazel Xiaohui Ang
RSRyan S. Soderquist
Ryan S. Soderquist
CEChristine E. Eyler
Christine E. Eyler
KWKris C. Wood
Kris C. Wood
Residual cancer cells that survive drug treatments with targeted therapies act as a reservoir from which eventual resistant disease emerges. Although there is great interest in therapeutically targeting residual cells, efforts are hampered by our limited knowledge of the vulnerabilities existing in this cell state. Here, we report that diverse oncogene-targeted therapies, including inhibitors of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), KRAS, and BRAF, induce DNA double-strand breaks and, consequently, ataxia-telangiectasia mutated (ATM)–dependent DNA repair in oncogene-matched residual tumor cells. This DNA damage response, observed in cell lines, mouse xenograft models, and human patients, is driven by a pathway involving the activation of caspases 3 and 7 and the downstream caspase-activated deoxyribonuclease (CAD). CAD is, in turn, activated through caspase-mediated degradation of its endogenous inhibitor, ICAD. In models of EGFR mutant non–small cell lung cancer (NSCLC), tumor cells that survive treatment with small-molecule EGFR-targeted therapies are thus synthetically dependent on ATM, and combined treatment with an ATM kinase inhibitor eradicates these cells in vivo. This led to more penetrant and durable responses in EGFR mutant NSCLC mouse xenograft models, including those derived from both established cell lines and patient tumors. Last, we found that rare patients with EGFR mutant NSCLC harboring co-occurring, loss-of-function mutations in ATM exhibit extended progression-free survival on first generation EGFR inhibitor therapy relative to patients with EGFR mutant NSCLC lacking deleterious ATM mutations. Together, these findings establish a rationale for the mechanism-based integration of ATM inhibitors alongside existing targeted therapies.

6 June 2022 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
KLKevin H. Lin
Kevin H. Lin
JRJustine C. Rutter
Justine C. Rutter
AXAbigail Xie
Abigail Xie
SKShane T. Killarney
Shane T. Killarney
CVCamille Vaganay
Camille Vaganay
KWKris C. Wood
Kris C. Wood

19 November 2024 in Cancer Discovery
Verified
Journal Article
Closed access
SKShane T. Killarney
Shane T. Killarney
GMGabriel Mesa
Gabriel Mesa
RWRachel Washart
Rachel Washart
BMBenjamin Mayro
Benjamin Mayro
KDKerry Dillon
Kerry Dillon
KWKris C. Wood
Kris C. Wood
Cancer cells exploit a mesenchymal-like transcriptional state (MLS) to survive drug treatments. Although the MLS is well characterized, few therapeutic vulnerabilities targeting this program have been identified. In this study, we systematically identify the dependency network of mesenchymal-like cancers through an analysis of gene essentiality scores in ∼800 cancer cell lines, nominating a poorly studied kinase, PKN2, as a top therapeutic target of the MLS. Coessentiality relationships, biochemical experiments, and genomic analyses of patient tumors revealed that PKN2 promotes mesenchymal-like cancer growth through a PKN2−SAV1−TAZ signaling mechanism. Notably, pairing genetic PKN2 inhibition with clinically relevant targeted therapies against EGFR, KRAS, and BRAF suppresses drug resistance by depleting mesenchymal-like drug-tolerant persister cells. These findings provide evidence that PKN2 is a core regulator of the Hippo tumor suppressor pathway and highlight the potential of PKN2 inhibition as a generalizable therapeutic strategy to overcome drug resistance driven by the MLS across cancer contexts. Significance: This work identifies PKN2 as a core member of the Hippo signaling pathway, and its inhibition blocks YAP/TAZ-driven tumorigenesis. Furthermore, this study discovers PKN2−TAZ as arguably the most selective dependency of mesenchymal-like cancers and supports specific inhibition of PKN2 as a provocative strategy to overcome drug resistance in diverse cancer contexts. See related commentary by Shen and Tan, p. 458

3 March 2025
Verified
Other
Open access
SKShane T. Killarney
Shane T. Killarney
GMGabriel Mesa
Gabriel Mesa
RWRachel Washart
Rachel Washart
BMBenjamin Mayro
Benjamin Mayro
KDKerry Dillon
Kerry Dillon
KWKris C. Wood
Kris C. Wood
-Supplemental Figure 1: Identification of a mesenchymal-like cancer dependency network. - Supplemental Figure 2: TAZ is a core dependency of mesenchymal-like cancer. - Supplemental Figure 3: PKN2 kinase activity inhibits MST1/2. - Supplemental Figure 4: PKN2 promotes resistance to oncogene-therapy induced resistance.

8 September 2026 in Cell Reports
Verified
Journal Article
Open access
CDChristopher D. Delaney
Christopher D. Delaney
MLMin Lu
Min Lu
SZSeth P. Zimmerman
Seth P. Zimmerman
YMYingying Meng
Yingying Meng
CVCamille Vaganay
Camille Vaganay
KWKris C. Wood
Kris C. Wood
Many cancers are driven by mutationally altered transcription factors (TFs) that rewire cells to an oncogenic state. Cells must activate specific mechanisms to tolerate the burden of oncogenic TF activity. To define such mechanisms, we focused on a canonical oncogenic fusion protein-driven cancer, alveolar rhabdomyosarcoma (ARMS), where the PAX3::FOXO1 fusion protein hyperactivates and mislocalizes PAX3 and FOXO1 TF functions. Employing sequential functional genomic CRISPR-Cas9 screens, we identified FANCM, a DNA translocase in the Fanconi anemia pathway, as a selective dependency in PAX3::FOXO1+ ARMS. FANCM loss reduces fusion protein levels, induces myogenic differentiation, and disrupts the PAX3::FOXO1 transcriptional program, thereby halting oncogenic proliferation. Mechanistically, FANCM depletion exacerbates replication stress (RS) and DNA damage signaling, with chromatin-associated RS enriched at PAX3::FOXO1 target gene loci, resulting in selective downregulation of the oncogenic program. CRISPR exon-tiling screens prioritized FANCM's helicase and DNA-binding domains as essential for this dependency, linking FANCM-mediated replication fork binding to sustained oncogenesis.

17 June 2026
Verified
Other
Open access
SKShane T. Killarney
Shane T. Killarney
GMGabriel Mesa
Gabriel Mesa
RWRachel Washart
Rachel Washart
BMBenjamin Mayro
Benjamin Mayro
KDKerry Dillon
Kerry Dillon
KWKris C. Wood
Kris C. Wood
Cancer cells exploit a mesenchymal-like transcriptional state (MLS) to survive drug treatments. Although the MLS is well characterized, few therapeutic vulnerabilities targeting this program have been identified. In this study, we systematically identify the dependency network of mesenchymal-like cancers through an analysis of gene essentiality scores in ∼800 cancer cell lines, nominating a poorly studied kinase, PKN2, as a top therapeutic target of the MLS. Coessentiality relationships, biochemical experiments, and genomic analyses of patient tumors revealed that PKN2 promotes mesenchymal-like cancer growth through a PKN2−SAV1−TAZ signaling mechanism. Notably, pairing genetic PKN2 inhibition with clinically relevant targeted therapies against EGFR, KRAS, and BRAF suppresses drug resistance by depleting mesenchymal-like drug-tolerant persister cells. These findings provide evidence that PKN2 is a core regulator of the Hippo tumor suppressor pathway and highlight the potential of PKN2 inhibition as a generalizable therapeutic strategy to overcome drug resistance driven by the MLS across cancer contexts.Significance:This work identifies PKN2 as a core member of the Hippo signaling pathway, and its inhibition blocks YAP/TAZ-driven tumorigenesis. Furthermore, this study discovers PKN2−TAZ as arguably the most selective dependency of mesenchymal-like cancers and supports specific inhibition of PKN2 as a provocative strategy to overcome drug resistance in diverse cancer contexts.See related commentary by Shen and Tan, p. 458